Join
Live feed
·
PRReleasevia Quantisnow
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA

ByQuantisnow·Wall Street's wire, on your screen.
JAZZ· Jazz Pharmaceuticals plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track JAZZ (Jazz Pharmaceuticals plc) and more on Quantisnow.

Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA | Quantisnow